MYOS - MYOS RENS Technology Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.53
+0.15 (+10.87%)
At close: 3:59PM EST

1.53 0.00 (0.00%)
After hours: 4:50PM EST

Stock chart is not supported by your current browser
Previous Close1.38
Open1.44
Bid1.47 x 500
Ask1.56 x 1600
Day's Range1.38 - 1.62
52 Week Range1.03 - 3.93
Volume460,050
Avg. Volume113,872
Market Cap9.707M
Beta1.84
PE Ratio (TTM)N/A
EPS (TTM)-0.67
Earnings DateMar 29, 2018 - Apr 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    MYOS RENS Technology to Showcase Fortetropin® and the Qurr® Line of Muscle Health Products at the 2018 Arnold Sports Festival in Columbus, OH from March 2-4, 2018

    Attendees of the Arnold Fitness EXPO can Sample Qurr® Powders, Puddings and Shakes, and Purchase Products with a Special Expo Discount at Booth #513. CEDAR KNOLLS, N.J., Feb. 15, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the fertilized egg yolk-based product that helps build lean muscle in conjunction with resistance training, announced today that it will showcase Fortetropin® at the Arnold Fitness EXPO to be held during the Arnold Sports Festival March 2-4, 2018, at the Greater Columbus Convention Center in Columbus, Ohio.

  • PR Newswirelast month

    MYOS RENS Technology Launches 30-Day Qurr® Fortetropin® Challenge

    CEDAR KNOLLS, N.J., Jan. 16, 2018 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that helps build lean muscle in conjunction with resistance training, today launched the Qurr® Fortetropin® Challenge (the "Challenge"), a new initiative that combines Fortetropin®-based Qurr® products with a workout and support plan designed by an award-winning and nationally certified personal trainer, Scott Keppel.

  • PR Newswirelast month

    MYOS RENS Technology CEO Issues Shareholder Letter

    Throughout 2017, we made significant strides in building a sustainable foundation that will allow us to fully leverage the market opportunities of Fortetropin®, our proprietary all-natural food ingredient that has been clinically shown to increase lean muscle size and mass when taken in conjunction with resistance training. Because MYOS is a science-based company, we are committed to making investments in research that explore the therapeutic potential of Fortetropin® across many broad areas of muscle health. As such, we have engaged with two prestigious universities known for excellence in research, to confirm long known anecdotal evidence of the efficacy of Fortetropin® in muscle building.

  • PR Newswire3 months ago

    MYOS RENS Technology Enters Into Research Agreement With University Of California, Berkeley To Study Effects Of Fortetropin® On Skeletal Muscle Protein Synthetic Rate In Older Men And Women

    Clinical Study will be Completed and its Results Announced in the Second Half of 2018 CEDAR KNOLLS, N.J. , Dec. 6, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") ...

  • PR Newswire3 months ago

    MYOS RENS Technology Reports Third Quarter 2017 Financial Results

    Revenue Increased 312% over prior year; Gross Profit Margin of 59% New Marketing programs with NFL Alumni, IMG College Expected to Strengthen Future Sales CEDAR KNOLLS, N.J. , Nov. 14, 2017 /PRNewswire/ ...

  • PR Newswire4 months ago

    MYOS RENS Technology Inc. Launches Collegiate Sports Marketing Platform

    CEDAR KNOLLS, N.J., Nov. 8, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a bionutrition company and owner of Fortetropin®, the natural food product that helps build lean muscle, today announced the debut of its collegiate sports marketing platform promoting the benefits of muscle health.

  • Who Really Owns MYOS RENS Technology Inc (MYOS)?
    Simply Wall St.4 months ago

    Who Really Owns MYOS RENS Technology Inc (MYOS)?

    In this article, I will take a quick look at MYOS RENS Technology Inc’s (NASDAQ:MYOS) recent ownership structure – an unconventional investing subject, but an important one. Ownership structure ofRead More...

  • PR Newswire4 months ago

    Pro Football Legends, the Commercial Marketing Arm of the NFL Alumni, Launches Partnership with MYOS RENS Technology Inc. in Optimal Bowl and Wellness Challenge

    CEDAR KNOLLS, N.J., Oct. 26, 2017 /PRNewswire/ -- NFL Alumni, under its commercial marketing arm Pro Football Legends, has announced a partnership with MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company and the owner of Fortetropin®, the world's first all-natural clinically demonstrated myostatin reducer, in support of the NFL Alumni NY/NJ Chapter's Optimal Bowl and Wellness Challenge.

  • PR Newswire5 months ago

    MYOS RENS Technology Inc. Appoints Joseph Mannello as Permanent Chief Executive Officer

    CEDAR KNOLLS, N.J., Sept. 20, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a biotherapeutics and bionutrition company, today announced that it has entered into an employment agreement with Joseph Mannello to serve as its permanent Chief Executive Officer, effective August 24, 2017. As part of his employment agreement, Mr. Mannello agreed to forego an annual salary (except for a legally required minimum amount) and instead received a stock option to purchase 300,000 shares of the Company's common stock at an exercise price of $4.00 per share, which option vests in eight quarterly installments.

  • PR Newswire7 months ago

    MYOS RENS to Introduce the Qurr® Line of Muscle Health Products at 35th IDEA World Convention July 19-23, 2017 in Las Vegas

    CEDAR KNOLLS, N.J., July 12, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), announced today that it will be a sponsor at this year's IDEA World Convention in Las Vegas to "put its money where its mouth is" with a 90-day money back guarantee on their Qurr Fortetopin® line of muscle health products.  MYOS is assuring customers that they will see results in 90 days using Qurr Fortetropin® powders or shakes in conjunction with resistance training– or they can get their money back.

  • MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
    Capital Cube9 months ago

    MYOS RENS Technology, Inc. :MYOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017

    Categories: Yahoo FinanceGet free summary analysis MYOS RENS Technology, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of MYOS RENS Technology, Inc. – GTx, Inc., Omeros Corporation, Xencor, Inc. and XOMA Corporation (GTXI-US, OMER-US, XNCR-US and XOMA-US) that have also reported for this period. Highlights ... Read more (Read more...)

  • PR Newswire10 months ago

    MYOS RENS Will Be Silver Sponsor at International Conference on Frailty and Sarcopenia Research (ICFSR)

    CEDAR KNOLLS, N.J., April 24, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") (MYOS), a company focused on the discovery, development and commercialization of muscle health and performance products, announced today that it will be a Silver Sponsor at the upcoming International Conference on Frailty and Sarcopenia Research (ICFSR), to be held April 27-29, 2017 in Barcelona, Spain. MYOS will be using this event as a platform for introducing clinicians to Qurr Well, their new line of functional nutrition products targeted at improving musculoskeletal health in aging adults. "We are pleased to be a sponsor at the upcoming International Conference on Frailty and Sarcopenia Research, and to have the opportunity to showcase the Qurr Well portfolio of products that may provide a solution to age-related muscle loss in adults by increasing lean muscle mass," stated Joseph Mannello, interim CEO of MYOS.

  • PR Newswire10 months ago

    MYOS RENS enters into agreement with Kansas State University to study impact of Fortetropin® on reducing muscle loss in dogs after joint surgery

    CEDAR KNOLLS, N.J., April 18, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. (MYOS) has entered into an agreement with the College of Veterinary Medicine at Kansas State University to study the impact of Fortetropin® on reducing muscle loss in dogs after ligament tear repair surgery.  The study continues the Company's investment in research regarding the therapeutic potential of Fortetropin® across many broad areas of muscle health. "The rationale for pursuing this study with Kansas State is two-fold," commented Joseph Mannello, Interim Chief Executive Officer of MYOS RENS.  "One of our goals is to evaluate Fortetropin®'s potential to improve musculoskeletal health in dogs.  A positive result could lay the foundation for the creation of a companion animal (pet) nutrition business focused on musculoskeletal health.  This could have a substantial benefit to MYOS RENS since the global animal health market, now at about $35 billion, is projected to reach $44.2 billion by 2020.  Positive results from this study would also lead to testing and developing Fortetropin®-based products to aid humans recovering from musculoskeletal surgeries.

  • PR Newswire11 months ago

    MYOS RENS Technology to host April 4 interactive conference call on "Qurr" product launch

    CEDAR KNOLLS, N.J., March 31, 2017 /PRNewswire/ -- Interested parties may access the call as follows: Event Title:  Management Highlights Event Date: 4/4/17 Event Time: 11:00 AM EDT Live Participant Dial-In:                   ...

  • PR Newswire11 months ago

    Are you Qurr-ious? MYOS Rens Technology Inc. Launches Qurr Product Line Powered by Fortetropin®, an All-Natural Ingredient Clinically Proven to Increase Muscle Size and Mass

    CEDAR KNOLLS, N.J., March 13, 2017 /PRNewswire/ -- MYOS RENS Technology Inc. ("MYOS" or "the Company") ( NASDAQ : MYOS ), today announced the launch of its much anticipated Qurr product line, which is available for both individual product purchase and subscription orders from the Qurr.com e-commerce site and educational portal. Qurr products, available in delicious powders, puddings and shakes, contain MYOS' proprietary ingredient Fortetropin®, which is clinically shown to reduce serum myostatin levels and increase lean muscle size and mass. "Muscle is critical to our overall well-being and we are thrilled to offer products developed to build healthy muscles which provide a foundation for full-body health and overall healthy living," said Joseph Mannello, CEO of MYOS.

  • Marketwiredlast year

    'Qurr' line of revolutionary muscle-health and muscle-building products in newly-enhanced form set for March rollout

    MYOS RENS Technology Inc. , today announced the upcoming launch of Qurr, its Fortetropin®-powered product line formulated to support the vital role of muscle in overall well-being as well as in fitness....